Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
6826 Stock Chart & Stats
HK$24.90
-HK$0.40(-1.57%)
At close: 4:00 PM EST
HK$24.90
-HK$0.40(-1.57%)
Day’s Range― - ―
52-Week RangeHK$21.70 - HK$31.28
Previous CloseN/A
Volume220.22K
Average Volume (3M)211.55K
Market Cap
HK$9.37B
Enterprise ValueHK$5.34B
Total Cash (Recent Filing)HK$2.52B
Total Debt (Recent Filing)HK$398.67M
Price to Earnings (P/E)20.8
Beta0.81
Next Earnings
Apr 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.28%
Share Statistics
EPS (TTM)-0.26
Shares Outstanding35,929,040
10 Day Avg. Volume238,704
30 Day Avg. Volume211,551
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.94
Price to Sales (P/S)2.13
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.28
Revenue Forecast (FY)HK$3.01B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageLow leverage and a conservative capital structure provide durable financial flexibility: the company can fund R&D, absorb demand shocks, pursue selective M&A or capex without relying heavily on external debt, and sustain operations through multi-quarter revenue softness.
Positive Operating Cash Flow And Growing FCFConsistent operating cash generation and improving free cash flow underpin long-term self-funding capacity. This supports reinvestment in product development, working capital needs, and shareholder returns while reducing reliance on capital markets during multi-quarter cycles.
Diversified Ophthalmology And Aesthetics Product PortfolioA product mix spanning surgical ophthalmology and medical aesthetics creates durable revenue diversification across clinical and elective channels. Structural demand from aging populations and ongoing aesthetic procedures supports medium-term procedure volumes and reduces single-market dependency.
Bears Say
Recent Revenue DeclineA sustained decline in top-line growth erodes scale benefits and reduces levers for margin recovery. If procedure volumes or market share do not rebound, the company may face greater pressure on pricing, R&D returns and its ability to fund growth organically over the next several quarters.
Margin Compression And Weaker ProfitabilityMaterial margin contraction and declining returns on equity signal structural pressure on pricing, cost base or product mix. Lower profitability reduces retained earnings and free cash generation, limiting capacity to invest in new products or defend market position over time.
Inconsistent Cash Conversion And Past Negative FCFVariable cash conversion and historical negative FCF increase financing and operational risk during downturns. This inconsistency can force trade-offs between capex, R&D and distributions, and makes long-term planning and margin recovery more difficult if working-capital drag persists.
Shanghai Haohai Biological Technology Co., Ltd. Class H News
6826 FAQ
What was Shanghai Haohai Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Haohai Biological Technology Co., Ltd. Class H lowest stock price was HK$21.70 and its highest was HK$31.28 in the past 12 months.
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap is HK$9.37B.
When is Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Apr 25, 2026 which is in 19 days.
How were Shanghai Haohai Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Haohai Biological Technology Co., Ltd. Class H released its earnings results on Mar 20, 2026. The company reported -HK$0.26 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.26.
Is Shanghai Haohai Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Haohai Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Haohai Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Haohai Biological Technology Co., Ltd. Class H pays a Quarterly dividend of HK$0.438 which represents an annual dividend yield of 4.28%. See more information on Shanghai Haohai Biological Technology Co., Ltd. Class H dividends here
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Haohai Biological Technology Co., Ltd. Class H have?
Shanghai Haohai Biological Technology Co., Ltd. Class H has 35,929,040 shares outstanding.
What happened to Shanghai Haohai Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Haohai Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.26 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.726%.
Which hedge fund is a major shareholder of Shanghai Haohai Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6826
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Haohai Biological Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.53%
12-Months-Change
Fundamentals
Return on Equity
4.47%
Trailing 12-Months
Asset Growth
-0.70%
Trailing 12-Months
Company Description
Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a leading biotechnology company based in Shanghai, China, specializing in the research, development, production, and commercialization of innovative medical devices and biopharmaceuticals. The company primarily operates in the fields of surgical sutures, wound care products, and regenerative medicine, focusing on enhancing patient outcomes through advanced technology and high-quality products. Haohai is committed to innovation and is dedicated to providing superior healthcare solutions to both domestic and international markets.
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Options Prices
Currently, No data available
---